Targeting the HGF/MET pathway in gastric cancer
Mené sur 9 et 121 patients atteints d'un cancer avancé de l'estomac ou de la jonction œso-gastrique, cet essai de phase Ib/II évalue la toxicité et l'efficacité, du point de vue de la survie sans progression, de l'ajout de rilotumumab, un anticorps monoclonal neutralisant le facteur de croissance des hépatocytes, à une chimiothérapie combinant épirubicine, cisplatine et capécitabine
The receptor tyrosine kinase MET is the cell surface receptor for hepatocyte growth factor (HGF). HGF-mediated activation of MET results in a complex genetic programme referred to as invasive growth, consisting of a series of processes, including proliferation, invasion, and angiogenesis, that occur under normal physiological conditions during embryonic development and pathologically during oncogenesis. The HGF/MET axis is activated in a range of cancers including gastric cancer, and is associat ...
The Lancet Oncology , commentaire, 2013